RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

DISEASE CHARACTERISTICS:

* Histologically confirmed adenocarcinoma

  * Metastatic or recurrent disease
  * Not curable by standard therapies
* Must have failed at least 1, but no more than 3, prior therapies for metastatic or recurrent disease

  * Patients with colorectal or breast adenocarcinoma must have failed at least 2 prior therapies
  * Must have had at least stable disease for 3 months while on last treatment prior to most recent disease progression
* Meets 1 of the following criteria:

  * At least 1 measurable site of disease ≥ 2 cm by radiography
  * Evaluable disease that could be reliably and consistently followed, as deemed by the principal investigator
* RAAG12 expression confirmed\* by immunohistochemistry NOTE: \*Not required for patients with colon, pancreatic, or gastric adenocarcinoma
* No evidence of residual or recurrent CNS metastases
* Hormone receptor status:

  * Not specified

PATIENT CHARACTERISTICS:

Age

* 18 and over

Sex

* Not specified

Menopausal status

* Not specified

Performance status

* ECOG 0-1

Life expectancy

* More than 3 months

Hematopoietic

* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 9.0 g/dL (transfusions allowed)
* Absolute neutrophil count ≥ 1,500/mm\^3

Hepatic

* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* AST and ALT ≤ 2.5 times ULN
* Alkaline phosphatase ≤ 2.5 times ULN
* γ-glutamyl transferase ≤ 2.5 times ULN
* Adequate hepatic function sufficient to undergo study therapy

Renal

* Creatinine \< 1.5 mg/dL
* Adequate renal function sufficient to undergo study therapy

Cardiovascular

* No New York Heart Association class III or IV heart disease
* No thrombosis within the past 3 months, including any of the following:

  * Deep vein thrombosis
  * Myocardial infarction
  * Stroke
* Adequate cardiac function sufficient to undergo study therapy

Pulmonary

* No pulmonary embolism within the past 3 months
* No significant pulmonary compromise, particularly dependence on supplemental oxygen on an as-needed or continuous basis
* Adequate pulmonary function sufficient to undergo study therapy

Immunologic

* No active viral, bacterial or systemic fungal infection requiring parenteral therapy within the past 4 weeks
* No history of chronic or recurrent infection requiring continual antiviral, antifungal, or antibacterial agents
* No known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in study drug

Other

* Amylase and lipase normal
* No other primary malignancy within the past 3 years except for the following:

  * Treated non-melanoma skin cancer
  * Carcinoma in situ of the cervix by biopsy
  * Squamous intraepithelial lesion of the cervix by PAP smear
  * Localized prostate cancer (Gleason score \< 6)
  * Resected melanoma in situ
* No other serious medical condition that would preclude study participation
* No dementia or altered mental status that would preclude giving informed consent
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 3 months after study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

* At least 3 half-lives since prior monoclonal antibody therapy
* No concurrent vaccinations
* No concurrent prophylactic hematologic growth factors

Chemotherapy

* At least 4 weeks since prior chemotherapy

Endocrine therapy

* No concurrent steroids except for the following:

  * Inhaled, ophthalmic, or nasal steroids
  * Stable dose of oral prednisone (or equivalent) ≤ 10 mg/day

Radiotherapy

* At least 4 weeks since prior radiotherapy

Surgery

* More than 4 weeks since prior major surgery

Other

* More than 4 weeks since prior investigational agents
* Prior oral antiviral, antifungal, or antibacterial therapy allowed provided therapy was completed within the past week
* No other concurrent antineoplastic therapy
* No concurrent immunosuppressive medications
* No other concurrent investigational agents
* No concurrent vitamins except those approved by the medical monitor

  * Concurrent daily multivitamin allowed
* Concurrent bisphosphonates allowed provided patient is on stable dose for ≥ 1 month prior to study entry